FDA MDEpiNet Panel: Device Surveillance Balancing Act
This article was originally published in The Gray Sheet
Executive Summary
“We want a system that knows enough not to trigger panic when it’s simply the steam of boiling water,…[but] perhaps there should be some alerting when the entire oven is on fire,” said Boston cardiologist Frederic Resnic at the annual gathering of the public-private Medical Device Epidemiology Network.
You may also be interested in...
FDA Post-Market Plan Gains Support, But Many Details Still Lacking
A diverse set of stakeholders backed FDA’s new proposed national post-market surveillance plan during a series of public meetings last week, but participants warned “the devil is in the details.”
FDA Post-Market Plan Gains Support, But Many Details Still Lacking
A diverse set of stakeholders backed FDA’s new proposed national post-market surveillance plan during a series of public meetings last week, but participants warned “the devil is in the details.”
CDRH Seeks To Expand Public-Private Medical Device Epidemiology Network
FDA hopes the MDEpiNet post-market surveillance program will be fully functional by the end of the year. A May public meeting is planned to catalyze the effort.